Navigation Links
Human C-reactive protein regulates myeloma tumor cell growth and survival
Date:9/10/2007

Scientists report that a protein best known as a common marker of inflammation plays a key role in the progression of human cancer. The research, published by Cell Press in the September issue of the journal Cancer Cell, implicates C-reactive protein (CRP) as a potential target for cancer treatment.

CRP is a protein that is made in the liver and secreted systemically during the process of inflammation in response to the inflammatory cytokine IL-6. The blood level of CRP is elevated in patients with infections, inflammatory diseases, some cardiovascular diseases, and malignancies including multiple myeloma (MM). Dr. Qing Yi and Dr. Jing Yang from the M.D. Anderson Cancer Center and colleagues designed a series of studies to investigate whether human CRP might influence the growth and survival of MM tumor cells.

The researchers found that addition of CRP to cell cultures at levels observed in patients with MM promoted myeloma cell proliferation and protected myeloma cells from chemotherapy-induced apoptosis and apoptosis induced by IL-6 withdrawal. The protective influence of CRP was also validated in a mouse model of myeloma.

The researchers went on to investigate the cell signaling pathways underlying CRP-mediated protection of myeloma cells. They demonstrated that CRP enhanced secretion of IL-6; binds activating Fcg receptors; activates PI3K/Akt, ERK, and NF-kB pathways; and inhibits caspase cascade activation induced by chemotherapy drugs. Further, CRP was shown to synergize with IL-6 in protecting myeloma cells from apoptosis.

These results provide strong evidence that CRP is not just a marker for MM but is a critical regulator of myeloma cell survival. CRP protects myeloma cells from apoptosis induced by chemotherapy drugs and stimulates myeloma cells to secrets more IL-6, which in turn provides additional protection to myeloma from apoptosis and stimulates liver cells to secrete more CRP. Thus, CRP could be a therapeutic target for breaking the vicious circle of myeloma to improve the therapeutic efficacy of currently available treatments, explains Dr. Yi.


'/>"/>

Contact: Nancy Wampler
nwampler@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. Human Genome Project Achieves Technological Triumph
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. Controversial deal on public access of the human genome map
4. Man against HIV – new vaccine ready for human trials
5. Scientists plan human cloning clinic in the United States
6. Human gene number increases
7. First human clone is near
8. Water regulation in humans
9. Fossil teeth and human development
10. Scientists found ancient Human Germ Killer
11. New standards for Human Research Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology: